JP7610308B2 - ペプチド及び該ペプチドを含む会合体又は組成物 - Google Patents

ペプチド及び該ペプチドを含む会合体又は組成物 Download PDF

Info

Publication number
JP7610308B2
JP7610308B2 JP2023577916A JP2023577916A JP7610308B2 JP 7610308 B2 JP7610308 B2 JP 7610308B2 JP 2023577916 A JP2023577916 A JP 2023577916A JP 2023577916 A JP2023577916 A JP 2023577916A JP 7610308 B2 JP7610308 B2 JP 7610308B2
Authority
JP
Japan
Prior art keywords
peptide
target
amino acid
region
acid residues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023577916A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2024004869A1 (https=
JPWO2024004869A5 (https=
Inventor
充訓 原田
昼也 吉田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MESCUE-JANUSYS INC.
Original Assignee
MESCUE-JANUSYS INC.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MESCUE-JANUSYS INC. filed Critical MESCUE-JANUSYS INC.
Publication of JPWO2024004869A1 publication Critical patent/JPWO2024004869A1/ja
Publication of JPWO2024004869A5 publication Critical patent/JPWO2024004869A5/ja
Application granted granted Critical
Publication of JP7610308B2 publication Critical patent/JP7610308B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
JP2023577916A 2022-06-29 2023-06-23 ペプチド及び該ペプチドを含む会合体又は組成物 Active JP7610308B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2022104662 2022-06-29
JP2022104662 2022-06-29
PCT/JP2023/023371 WO2024004869A1 (ja) 2022-06-29 2023-06-23 ペプチド及び該ペプチドを含む会合体又は組成物

Publications (3)

Publication Number Publication Date
JPWO2024004869A1 JPWO2024004869A1 (https=) 2024-01-04
JPWO2024004869A5 JPWO2024004869A5 (https=) 2024-06-04
JP7610308B2 true JP7610308B2 (ja) 2025-01-08

Family

ID=89382984

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023577916A Active JP7610308B2 (ja) 2022-06-29 2023-06-23 ペプチド及び該ペプチドを含む会合体又は組成物

Country Status (4)

Country Link
US (1) US20260092084A1 (https=)
EP (1) EP4549470A1 (https=)
JP (1) JP7610308B2 (https=)
WO (1) WO2024004869A1 (https=)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015056727A1 (ja) 2013-10-17 2015-04-23 国立大学法人 富山大学 低受胎率受精卵の発生率改善培地
JP2017525676A (ja) 2014-07-08 2017-09-07 ノースイースタン ユニバーシティ 疎水性薬物担体および抗菌剤としての使用のための両親媒性ペプチドナノ微粒子
JP2020186184A (ja) 2019-05-13 2020-11-19 国立研究開発法人理化学研究所 粒子を形成することが可能なペプチドを含む組成物
WO2021069913A1 (en) 2019-10-10 2021-04-15 King's College London Anti-cancer leucin-rich peptides and uses thereof
JP2021534828A (ja) 2018-08-30 2021-12-16 エイチシーダブリュー バイオロジックス インコーポレイテッド 多鎖キメラポリペプチドおよびその使用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015056727A1 (ja) 2013-10-17 2015-04-23 国立大学法人 富山大学 低受胎率受精卵の発生率改善培地
JP2017525676A (ja) 2014-07-08 2017-09-07 ノースイースタン ユニバーシティ 疎水性薬物担体および抗菌剤としての使用のための両親媒性ペプチドナノ微粒子
JP2021534828A (ja) 2018-08-30 2021-12-16 エイチシーダブリュー バイオロジックス インコーポレイテッド 多鎖キメラポリペプチドおよびその使用
JP2020186184A (ja) 2019-05-13 2020-11-19 国立研究開発法人理化学研究所 粒子を形成することが可能なペプチドを含む組成物
WO2021069913A1 (en) 2019-10-10 2021-04-15 King's College London Anti-cancer leucin-rich peptides and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
WANG, M et al.，In Situ Self-Assembly of Bispecific Peptide for Cancer Immunotherapy，Angewandte Chemie International Edition，2022年01月07日，Vol. 61，e202113649
YU, B et al.，A Hybrid Platform Based on a Bispecific Peptide-Antibody Complex for Targeted Cancer Therapy，Angewandte Chemie International Edition，2019年，Vol. 58，pp. 2005-2010
ZHOU, J et al.，In Silico Exploration and Biological Evaluation of Bispecific Peptides Derived from Anti-HER2 Antibodies and Peptide-Camptothecin Conjugates for HER2-Positive Breast Cancer，Journal of Medicinal Chamistry，2022年11月09日，Vol. 65，pp. 15123-15139

Also Published As

Publication number Publication date
JPWO2024004869A1 (https=) 2024-01-04
WO2024004869A1 (ja) 2024-01-04
US20260092084A1 (en) 2026-04-02
EP4549470A1 (en) 2025-05-07

Similar Documents

Publication Publication Date Title
Li et al. Chemical modification of M13 bacteriophage and its application in cancer cell imaging
KR101617790B1 (ko) 치료, 진단과 실험적 혼합물들의 운반을 위한 공학적으로 가변된 나노입자 및 치료용 관련 조성물
JP5390621B2 (ja) 二座ペプチドバインダー
EP2748182B1 (en) Peptide nanoparticles and uses thereof
JP5677453B2 (ja) Ｂｐｂベースのカーゴ運搬システム
KR20160138133A (ko) 안정화된 피브로넥틴 기반 스캐폴드 분자
JP7216031B2 (ja) 金属ナノクラスター足場
JP2016147909A (ja) 機能性ポリペプチド
US9938526B2 (en) Manganese ion coated nanoparticles for delivery of compositions into the central nervous system by nasal insufflation
Platt et al. Influence of multivalent nitrilotriacetic acid lipid− ligand affinity on the circulation half-life in mice of a liposome-attached his6-protein
JP7610308B2 (ja) ペプチド及び該ペプチドを含む会合体又は組成物
US7527792B1 (en) Pharmaceutical composition comprising an anti-cancer and at least a peptide
Garbujo et al. Functionalization of colloidal nanoparticles with a discrete number of ligands based on a “HALO-bioclick” reaction
WO2022138637A1 (ja) ナノ粒子形成ペプチド及びそのペプチドで形成されるナノ粒子
JP7068711B2 (ja) 細胞質送達ペプチド
Lopez‐Silva et al. Antibody Labeling With FITC Facilitates Controlled Release From Peptide Hydrogels Bearing Fc‐Binding Motifs
US20240285785A1 (en) Targeting sortilin
Darwish et al. Nanolipoprotein particles for co-delivery of cystine-knot peptides and Fab–based therapeutics
JP2021038184A (ja) 難水溶性薬物の複合体及びその製造方法
HK40090445A (zh) 靶组织特异性递送型药物递送系统用胶囊的用途
WO2025007748A9 (zh) 纳米递送系统、其制备方法和用途
KR20260028068A (ko) 펩티드와 회합된 나노입자 조성물
Boldt et al. Converting human proteins into precision polymer therapeutics
BAYELE et al. Protein Transduction by Lipidic Peptide Dendrimers
HK1259626B (zh) 使用碳硅烷树状高分子的药物递送系统用靶向型壳

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231218

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231218

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20231218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20231218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240405

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240528

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240725

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240924

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241121

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241210

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241213

R150 Certificate of patent or registration of utility model

Ref document number: 7610308

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150